ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0899

Complement Factor I (CFI) Gene Expression by Kidney Tubular Cells Is Increased in Lupus Nephritis Patients with Interstitial Fibrosis and Tubular Atrophy

Shudan Wang1, John Greally2, Masako Suzuki3, Jee-Young Moon2, Tao Wang2, Yvonne M Saenger2, Brad Rovin4 and J. Michelle Kahlenberg5, 1Albert Einstein College of Medicine / Montefiore Medical Center, New York, NY, 2Albert Einstein College of Medicine, Bronx, NY, 3Texas A&M University, College Station, TX, 4Ohio State University, Columbus, OH, 5University of Michigan, Ann Arbor, MI

Meeting: ACR Convergence 2023

Keywords: Bioinformatics, Biomarkers, complement, Gene Expression, Lupus nephritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (0899–0933) SLE – Etiology & Pathogenesis Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Tubulointerstitial injury is a strong predictor of progression to kidney failure in lupus nephritis (LN). Prior animal studies suggest intrarenal complement activation has an important and underrecognized role in tubulointerstitial fibrosis in LN, yet this has not been shown in LN patients. This study aimed to identify complement markers of tubulointerstitial fibrosis in LN and potential therapeutic targets. Tubular complement gene expression in LN kidneys from patients with and without interstitial fibrosis/tubular atrophy (IFTA) was compared using scRNA-seq data.

Methods: We used data from the Accelerating Medicine Partnership/ Multi-Ethnic Translational Research Optimization Lupus cohort, which applied scRNA-seq to 20 LN kidney tissue samples [1]. Cells between 200 and 2500 detected features were included. The data was normalized, scaled, and underwent principal component analysis and clustering using Uniform Manifold Approximation and Projection plots to identify distinct cell subtypes. Specific marker genes were used to identify the kidney tubular cell subtypes: ALDOB (proximal tubules), UMOD (loop of Henle), CALB1 (distal convoluted tubules), and SLC4A1/TMEM213 (collecting duct). Complement gene expression was compared between LN patients with and without IFTA in the overall tubular cells and in each tubular cell subtypes using two approaches: 1) subject-based analysis where the average gene expression per subject was calculated and compared between the groups using the Wilcoxon rank sum test. 2) single-cell analysis using a linear mixed effects model. IFTA was defined as ≥10% of interstitium with fibrosis and atrophy.

Results: Of the 20 LN patients, 9 had IFTA on kidney biopsy. Table 1 compares demographics, medication use, laboratory, and histopathology between LN patients with (≥ 10%) and without (< 10%) IFTA on biopsy. LN patients with IFTA had a higher proportion with tubulointerstitial inflammation as compared with those without IFTA (56% vs. 1%, p=0.05) and higher chronicity index median score 3 (IQR= 3, 4) vs 1(0,1). There was no difference in other variables. A total of 1162 kidney tubular cells were identified: 287 proximal tubular, 171 loop of Henle, 587 distal tubular and 117 collecting duct cells. LN patients with IFTA had significantly higher overall tubular expression of Complement Factor I (CFI) as compared to those without IFTA: median average expression 0.298 (0.258, 0.383) vs. 0.059 (0.019, 0.100), p=0.0005, Figure 1. No differential expression of other complement genes was found (Table 2). When evaluating each tubular cell subtype, no difference in average CFI expression was found. Single cell analysis also showed increased overall tubular expression of CFI (β=0.27, SE=0.05, p< 0.001) and C7 (β=0.31, SE=0.15, p=0.049) among LN patients with IFTA. Specifically, CFI expression was increased in the distal tubular cells (β=0.27, SE=0.06, p< 0.001) but not in the other tubular cell subtypes.

Conclusion: This study identifies CFI, a regulator of the alternative complement pathway, as a potential marker of IFTA in LN. Increased CFI has been found in other kidney diseases [2] and may overcompensate for a dysfunctional complement system.

Supporting image 1

Supporting image 2

Black line is over the median of each group. White line represents each subject.

Supporting image 3


Disclosures: S. Wang: None; J. Greally: None; M. Suzuki: None; J. Moon: None; T. Wang: None; Y. Saenger: None; B. Rovin: AstraZeneca, 2, 5, Aurinia, 2, 5, Biogen, 2, F. Hoffmann-La Roche Ltd, 2, Genentech, 2, GlaxoSmithKlein(GSK), 2, Novartis, 2; J. Kahlenberg: AstraZeneca, 1, Bristol-Myers Squibb(BMS), 2, 5, EMD Serano, 2, exo therapeutics, 2, Gilead, 2, GlaxoSmithKlein(GSK), 1, horizon Therapeutics, 2, Janssen, 5, Pfizer, 2, ROME Therapeutics, 2, 5, Rome Therapeutics, 5, Ventus Therapeutics, 2, 5.

To cite this abstract in AMA style:

Wang S, Greally J, Suzuki M, Moon J, Wang T, Saenger Y, Rovin B, Kahlenberg J. Complement Factor I (CFI) Gene Expression by Kidney Tubular Cells Is Increased in Lupus Nephritis Patients with Interstitial Fibrosis and Tubular Atrophy [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/complement-factor-i-cfi-gene-expression-by-kidney-tubular-cells-is-increased-in-lupus-nephritis-patients-with-interstitial-fibrosis-and-tubular-atrophy/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/complement-factor-i-cfi-gene-expression-by-kidney-tubular-cells-is-increased-in-lupus-nephritis-patients-with-interstitial-fibrosis-and-tubular-atrophy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology